|
May 6
|
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
|
|
May 4
|
Insider Sale at Day One Biopharmaceuticals Inc (DAWN)
|
|
Apr 23
|
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
|
|
Mar 15
|
Companies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In Growth
|
|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Feb 28
|
Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results
|
|
Feb 26
|
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
|
|
Dec 19
|
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 27
|
Milei to Send ‘Shock’ Package to Argentina’s Congress on Day One
|
|
Sep 12
|
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
|
|
Apr 26
|
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
|